Active Stocks
Thu Mar 28 2024 14:19:25
  1. Tata Steel share price
  2. 156.15 2.16%
  1. HDFC Bank share price
  2. 1,456.50 1.10%
  1. ITC share price
  2. 432.80 1.12%
  1. Power Grid Corporation Of India share price
  2. 278.05 2.58%
  1. State Bank Of India share price
  2. 758.60 3.34%
Business News/ Companies / Lupin, Cadila Healthcare recall drugs in US
BackBack

Lupin, Cadila Healthcare recall drugs in US

Lupin and Cadila Healthcare are recalling nearly 1.11 lakh units of Duloxetine capsules and 19,812 bottles of Paroxetine tablets, says the US FDA

Lupin is recalling 1,11,648 units of Duloxetine delayed-release capsules USP, in the strength of 30 mg, on account of failed dissolution specification. Photo: iStockPremium
Lupin is recalling 1,11,648 units of Duloxetine delayed-release capsules USP, in the strength of 30 mg, on account of failed dissolution specification. Photo: iStock

New Delhi: Drug firms Lupin Ltd and Cadila Healthcare Ltd are recalling nearly 1.11 lakh units of Duloxetine delayed-release capsules and 19,812 bottles of Paroxetine tablets, respectively, from the US market, the US health regulator has said.

Lupin is recalling 1,11,648 units of Duloxetine delayed-release capsules USP, in the strength of 30 mg, on account of failed dissolution specification, the US Food and Drug Administration (USFDA) said in its latest enforcement report. The drug was manufactured by Lupin Goa, the report added. The ongoing voluntary nationwide recall is a class III recall, it said.

Zydus Pharmaceuticals USA Inc, a unit of Cadila Healthcare, is also recalling 19,812 bottles of Paroxetine tablets in the strength of 30 mg from the US market. The reason for the ongoing voluntary nationwide recall is “presence of foreign tablets/capsules: Risperidone tablets were found in bottle of Paroxetine tablets", the report stated. The product was manufactured by Cadila Healthcare and the recall is a class II recall, the regulator added.

A class II recall is initiated in a “situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote". A class III recall, on the other hand, kicks in where use of or exposure to a violative product is not likely to cause adverse health consequences.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 07 Dec 2017, 05:01 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie